annb0t
Top 20
One thing we could say about the analysts on Mayne Pharma Group Limited (ASX:MYX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business.
Following the latest downgrade, the current consensus, from the three analysts covering Mayne Pharma Group, is for revenues of AU$412m in 2023, which ...
>>> Read more: Analysts Are More Bearish On Mayne Pharma Group Limited (ASX:MYX) Than They Used To Be
Following the latest downgrade, the current consensus, from the three analysts covering Mayne Pharma Group, is for revenues of AU$412m in 2023, which ...
>>> Read more: Analysts Are More Bearish On Mayne Pharma Group Limited (ASX:MYX) Than They Used To Be
